Recursion Pharmaceuticals (RXRX) Stock
Recursion Pharmaceuticals (RXRX) closed at $2.91 on Nov 16, 2026; its Tenet Score is 53 of 100 against 313 Healthcare peers.
21 figures withheld by our checks. Each blank figure names its reason.
Key stats
- Previous close
- $2.91
- Nov 16, 2026
- Market cap
- $2.0B
- share price × the latest quarter's diluted weighted-average share count (vendor)
- 52-week range
- 2.77 – 5.24
- low → high · as of close, Nov 13, 2026
- Tenet Score
- 53/100
- Mixed · 313 Healthcare peers
Industry: Drugs
Recursion Pharmaceuticals Inc scores 53/100. Mixed. Strongest on value and financial health, quality is the soft spot versus 313 Healthcare peers.
Tenet Score · vs sector
n=313Factor grades
Price
The whole report, at a glance · every card is a live peek, click any to open the section
- ✕ Buffett Quality
- ✕ Piotroski F-Score
- ✕ Graham Defensive
- ✕ Quality Compounder
- ✕ Drawdown Context
- ✕ Reversal Evidence
13F flows & insider trades land here.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery…
Similar-sized companies in Drugs
The 10 companies in this industry closest in market cap, as of Nov 13, 2026.
| Company | Tenet Score | Market cap |
|---|---|---|
| Schrodinger IncSDGR | 41 | $2.2B |
| Immunome IncIMNM | 49 | $2.2B |
| Aurinia Pharmaceuticals IncAUPH | 83 | $2.1B |
| Vera Therapeutics IncVERA | 42 | $2.0B |
| Harmony Biosciences Holdings IncHRMY | 81 | $2.0B |
| Veracyte IncVCYT | 78 | $2.0B |
| Maravai LifeSciences Holdings IncMRVI | 29 | $2.0B |
| Biocryst Pharmaceuticals Inc.BCRX | 73 | $2.0B |
| Agios Pharmaceuticals IncAGIO | 64 | $1.9B |
| Eton Pharmaceuticals IncETON | 47 | $1.8B |
Common questions
What sector and industry is Recursion Pharmaceuticals in?
Recursion Pharmaceuticals is in the Healthcare sector and the Drugs industry.
What is Recursion Pharmaceuticals' Tenet Score?
Recursion Pharmaceuticals' Tenet Score is 53 out of 100, ranked against 313 Healthcare peers as of Nov 13, 2026.




